Where does OptiNose Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), OptiNose Inc. ranks #36,824 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does OptiNose Inc. hold?

OptiNose Inc. holds 7 US utility patents granted between 2023 and 2024, spanning 3 technology areas.

What is OptiNose Inc.'s Innovation Score?

OptiNose Inc. has an Innovation Score of 45.0 out of 100 (top 24% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is OptiNose Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for OptiNose Inc..

What does claim depth mean for OptiNose Inc.'s patents?

OptiNose Inc.'s patents average 19.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the OptiNose Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

OptiNose Inc.

Q: What technology areas does OptiNose Inc. focus on?

OptiNose Inc.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 7 patents, ranking #969 of 3,490 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2023–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Optinose ranks #36,824 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.

#36,824
of 49,997 US assignees by volume: Top 24%
by Innovation Score (45.0/100): 19.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R36824 · US Corporation #36,824 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #36,824/49,997
PHOTO-FINISH Openstream
CPC-NARROW A61M · 3 areas
INNOV-PAR 45.0/100
CLAIMS-RICH 19.6 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2023–2024 · 2y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Openstream Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Optinose’s 45.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (16%) Velocity 20.0 pts (44%) Breadth 6.1 pts (14%) Claim depth 11.7 pts (26%)

Qualcomm Incorporated · highest

85
OptiNose · this assignee

45
3D Lighting… · lowest

7

What this shows Optinose's Innovation Score is 45.0/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Optinose?

Each dot is one of Optinose’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Optinose’s own 19.6 claims/patent is at or below the 21.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Optinose vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Optinose's grants concentrate

OptiNose Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2023 (6 grants) versus a trough of 1 in 2024. By volume, Optinose sits between Openstream Inc. and Optikos Corporation.

Optinose's three-year grant acceleration

OptiNose Inc. shows 7 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Openstream

7
Opentrons Labworks

7
Opera Solutions U…

7
Operation and Dat…

7
Optical Fiber Pac…

7
Optical Physics

7
Optics Innovation

7
Optikos

7
Optinose ◀

7

What this shows OptiNose holds 7 patents at rank #36,831, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near OptiNose

By rank, the assignees closest to #36,831 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in OptiNose's primary technology class.

Optinose's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

OptiNose Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	6	85.7%
2024	1	14.3%

Which technologies does OptiNose Inc. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

OptiNose Inc.'s patent record in context - here's where to go next.

OptiNose Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #36,824 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare OptiNose Inc. against Openstream Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.